Prosecution Insights
Last updated: November 04, 2026
Application No. 17/698,900

DETERMINATION OF COPY NUMBER VARIATIONS USING BINOMIAL PROBABILITY CALCULATIONS

Non-Final OA §101§112§DP
Filed
Mar 18, 2022
Priority
Sep 07, 2011 — provisional 61/531,738 +2 more
Examiner
WHALEY, PABLO S
Art Unit
3619
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
Ariosa Diagnostics, Inc.
OA Round
3 (Non-Final)
25%
Grant Probability
At Risk
3-4
OA Rounds
7m
Est. Remaining
46%
With Interview

Examiner Intelligence

Grants only 25% of cases
25%
Career Allowance Rate
136 granted / 544 resolved
-27.0% vs TC avg
Strong +21% interview lift
Without
With
+21.4%
Interview Lift
resolved cases with interview
Typical timeline
5y 2m
Avg Prosecution
34 currently pending
Career history
595
Total Applications
across all art units

Statute-Specific Performance

§101
28.7%
-11.3% vs TC avg
§103
25.0%
-15.0% vs TC avg
§102
4.9%
-35.1% vs TC avg
§112
32.8%
-7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 544 resolved cases

Office Action

§101 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 05/29/2026 has been entered. Applicant's amendments and remarks, filed 05/29/2026, are acknowledged. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Priority Applicant’s claim for the benefit of priority under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. The present application is a divisional of U.S. Application Ser. No. 14/176,830, filed February 10, 2014, which is a continuation application of U.S. Application Ser. No. 13/605,505, filed September 6, 2012, which claims priority to U.S. Application Ser. No. 61/531,738, filed September 7, 2011. Status of Claims Claims 3-8 are under examination. Claims 1-2 are cancelled. Withdrawn Rejections The rejection of claims 3-8 under 35 U.S.C. 103(a) as being unpatentable over Struble et al. (US2012/0190018; filed: Oct. 15, 2011; Priority date: 1/25/2011) is withdrawn in view of the provided “Statement of Common Ownership” (on page 14 of the response), which is consistent with the guidance provided in MPEP 717. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. The following rejection is modified in view of applicant’s amendments. Claims 3-8 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more. The United States Patent and Trademark Office published revised guidance on the application of 35 U.S.C. § 101. USPTO’s 2019 Revised Patent Subject Matter Eligibility Guidance (“Guidance”). Under the Guidance, in determining what concept the claim is “directed to,” we first look to whether the claim recites: (1) any judicial exceptions, including certain groupings of abstract ideas (i.e., mathematical concepts, certain methods of organizing human activity such as a fundamental economic practice, or mental processes) (Guidance Step 2A, Prong 1); and (2) additional elements that integrate the judicial exception into a practical application (see MPEP § 2106.05(a)-(c), (e)-(h)) (Guidance Step 2A, Prong 2). Only if a claim (1) recites a judicial exception and (2) does not integrate that exception into a practical application, do we then look to whether the claim contains an “‘inventive concept’ sufficient to ‘transform’” the claimed judicial exception into a patent-eligible application of the judicial exception. Alice, 573 U.S. at 221 (quoting Mayo, 566 U.S. at 82). In so doing, we thus consider whether the claim: (3) adds a specific limitation beyond the judicial exception that are not “well-understood, routine and conventional in the field” (see MPEP § 2106.05(d)); or 2019 Revised Patent Subject Matter Eligibility Guidance, 84 Fed. Reg. 50-57 (January 7, 2019). (4) simply appends well-understood, routine, conventional activities previously known to the industry, specified at a high level of generality, to the judicial exception.(Guidance Step 2B). See Guidance, 84 Fed. Reg. at 54-56. Guidance Step 1: The instant invention (claim 3 being representative) is directed to a method, computer readable medium and system that performs a process. Thus, the claims are directed to one of the statutory categories of invention. MPEP 2106.03. A. Guidance Step 2A, Prong 1 The Revised Guidance instructs us first to determine whether any judicial exception to patent eligibility is recited in the claim. The Revised Guidance identifies three judicially-excepted groupings identified by the courts as abstract ideas: (1) mathematical concepts, (2) certain methods of organizing human behavior such as fundamental economic practices, and (3) mental processes. Regarding claim(s) 1, the claimed steps that are part of the abstract idea are as follows: accessing…a first data set comprising frequency data based on identification of distinguishing regions of the thirty-two for one or more informative loci from the maternal source in the mixed sample; accessing…a second data set comprising frequency data for one or more informative loci from a fetal source in the mixed sample; calculating…an estimated fetal source contribution of cell free nucleic based on a binomial distribution of the counts of distinguishing regions from first and second data sets; accessing…a third data set comprising frequency data for two or more genomic regions from the combined maternal and fetal sources in the mixed sample; calculating…the presence or absence of a CNV for one or more genomic regions in the fetus by comparing empirical copy numbers…or more genomic regions from the combined maternal and fetal sources in the mixed sample to the estimated fetal source contribution of cell free nucleic acids in the mixed sample. Mental Processes Under MPEP §2111, during patent examination, claims must be interpreted in their broadest reasonable manner consistent with the specification. This means that examiners consider the claim language in light of the specification as understood by a person of ordinary skill in the art, ensuring that the claims are not unduly narrowed by implicit limitations not explicitly recited in the claim (37 CFR 1.75(d)(1)). With regards to the “accessing” steps, a claim “recites” a judicial exception when the judicial exception is “set forth” or “described” in the claim. MPEP 2106.04, subsection II. In this case, under the BRI, the recited acts of accessing data sets forth or describes observing and/or manipulating data to generate additional data. Moreover, scientists routinely observe data and this can be done in the mind or using a pencil/paper. As such, this step encompasses a mental process of observing data and/or manipulating data. MPEP 2106.04(a)(2), section III. With regards to the “calculating” steps, under the BRI, the recited acts of calculating set forth or describe manipulating data to generate additional data. Moreover, scientists routinely manipulate and/or analyze (i.e. compare) data and this can be done in the mind or using a pencil/paper. As such, this step encompasses a mental process of observing data and/or manipulating data. MPEP 2106.04(a)(2), section III. It is important to note that “Claims that recite performing information analysis as well as the collection and manipulation of information related to such analysis, have been determined by our reviewing court to be an abstract concept that is not patent eligible. See SAP, 898 F.3d, 1165, 1167, 1168 (Claims reciting "[a] method for providing statistical analysis" (id. at 1165) were determined to be "directed to an abstract idea" (id. at 1168)); see also Content Extraction & Transmission LLC v. Wells Fargo Bank, Nat'l Ass 'n, 776 F.3d 1343, 1345, 1347 (Fed. Cir. 2014) (finding the "claims generally recite ... extracting data ... [and] recognizing specific information from the extracted data" and that the "claims are drawn to the basic concept of data recognition"). "As many cases make clear, even if a process of collecting and analyzing information is limited to particular content or a particular source, that limitation does not make the collection and analysis other than abstract." SAP, 898 F.3d at 1168 (internal quotation marks omitted))." [Step 2A, Prong 1: YES]. Mathematical Concept With regards to said calculating, a claim “recites” a judicial exception when the judicial exception is “set forth” or “described” in the claim. MPEP 2106.04, subsection II. In this case, under the BRI, the recited acts of calculating data (based on binomial distributions) and comparing different types of data sets forth or describes a mathematical calculation and/or mathematical relationship. This position is further supported by applicant’s own specification, which teaches equations for performing said calculations [pages 8, 21, 22]. As such, these steps recite a mathematical concept. MPEP 2106.04(a)(2) Section I. [Step 2A, Prong 1: YES]. Natural Correlation Under the broadest reasonable interpretation, the instant claims require obtaining sequence information from a sample and correlating this with scores that are indicative of CNV. Therefore, the claimed invention amounts to identifying a naturally occurring relationship between data and disease. See MPEP 2106.04(b). It is noted that even if a claim does recite a law of nature or natural phenomenon, it may still be eligible. For example, claims reciting a naturally occurring relationship between a patient’s genotype and the risk of QTc prolongation (a law of nature) were held eligible as not “directed to” that relationship because they also recited a step of treating the patient with an amount of a particular medication that was tailored to the patient’s genotype. Vanda Pharms., 887 F.3d at 1134-36, 126 USPQ2d at 1279-81. This particular treatment step applied the natural relationship in a manner that integrated it into a practical application. The court’s analysis in Vanda is equivalent to a finding of eligibility at Step 2A Prong Two (Pathway B). B. Guidance Step 2A, Prong 2 Having made that determination, under the 2019 Guidance, the examiner next determines whether there are additional elements beyond the recited abstract idea(s) that integrate them into a practical application. In this case, the additional elements that are not part of the abstract idea are as follows: measuring a frequency of thirty-two or more informative loci from the fetal source in the mixed sample and a frequency of thirty-two or more informative loci from the maternal source in the mixed sample; computer processor and computer readable medium (as in claims 3, 5, 7, and 8) With regards to said measuring, this step is not limited to any acts or operations and amounts to necessary gathering of data for use by the abstract idea. As such, this step amounts to “insignificant extra-solution activity” and does not integrate the judicial exception into a practical application. See MPEP 2106.05(g). With regards to the claimed processor and CRM, these elements are recited at high level of generality and are merely being used as tools to perform generic computer functions or the abstract idea. As such, these elements amount to no more than mere instructions to apply the exception using a generic computer. See MPEP 2106.05(f). Even when viewed in combination, these additional steps/elements do not integrate the recited judicial exception into a practical application. [Step 2A, Prong 2: NO]. For a list of considerations when evaluating whether additional elements integrate a judicial exception into a practical application see MPEP 2106.04(d)(1) lists the following example considerations for evaluating whether a judicial exception is integrated into a practical application: An improvement in the functioning of a computer or an improvement to other technology or another technical field, as discussed in MPEP §§ 2106.04(d)(1) and 2106.05(a); Applying or using a judicial exception to effect a particular treatment or prophylaxis for a disease or medical condition, as discussed in MPEP § 2106.04(d)(2); Implementing a judicial exception with, or using a judicial exception in conjunction with, a particular machine or manufacture that is integral to the claim, as discussed in MPEP § 2106.05(b); Effecting a transformation or reduction of a particular article to a different state or thing, as discussed in MPEP § 2106.05(c); and Applying or using the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technological environment, such that the claim as a whole is more than a drafting effort designed to monopolize the exception, as discussed in MPEP § 2106.05(e). C. Guidance Step 2B: This part of the eligibility analysis evaluates whether the claim as a whole amount to significantly more than the recited exception i.e., whether any additional element, or combination of additional elements, adds an inventive concept to the claim. See MPEP 2106.05. As discussed above, the non-abstract steps/elements amount to nothing more than insignificant extra-solution activity. A review of the specification teaches routine and conventional methods for measuring ‘loci’ frequency (e.g. sequencing or ‘counting’) [0015, 0061] and teaches routine and conventional computer hardware elements for performing the claimed method [0074-0077 and Figure 1]. Moreover, the courts have recognized the following laboratory techniques as well-understood, routine, conventional activity in the life science arts when they are claimed in a merely generic manner (e.g., at a high level of generality) or as insignificant extra-solution activity: i. Determining the level of a biomarker in blood by any means, Mayo, 566 U.S. at 79, 101 USPQ2d at 1968; Cleveland Clinic Foundation v. True Health Diagnostics, LLC, 859 F.3d 1352, 1362, 123 USPQ2d 1081, 1088 (Fed. Cir. 2017); ii. Using polymerase chain reaction to amplify and detect DNA, Genetic Techs. Ltd. v. Merial LLC, 818 F.3d 1369, 1376, 118 USPQ2d 1541, 1546 (Fed. Cir. 2016); Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1377, 115 USPQ2d 1152, 1157 (Fed. Cir. 2015); iii. Detecting DNA or enzymes in a sample, Sequenom, 788 F.3d at 1377-78, 115 USPQ2d at 1157); Cleveland Clinic Foundation 859 F.3d at 1362, 123 USPQ2d at 1088 (Fed. Cir. 2017); v. Analyzing DNA to provide sequence information or detect allelic variants, Genetic Techs. Ltd., 818 F.3d at 1377; 118 USPQ2d at 1546; Therefore, even upon reconsideration, there is nothing unconventional with regards to the above non-abstract elements/steps. See MPEP 2106.05(d)(Part II). Thus, the independent claim(s) as a whole do not amount to significantly more than the exception itself. Therefore, the claim(s) is/are not patent eligible. [Step 2B: NO]. D. Dependent Claims Dependent claims 4 and 6, have also been considered under the two-part analysis but do not include additional steps/elements appended to the judicial exception that are sufficient to amount to significantly more than the judicial exception(s) for the following reasons. In particular, claims 4 and 6 are directed to limitations that further limit the specificity of the abstract idea set forth above. Accordingly, these claims are also directed to an abstract idea for the reasons set forth above (Step 2A, prong 1 analysis). Therefore, the instantly rejected claims are not drawn to eligible subject matter as they are directed to an abstract idea (and/or natural correlation) without significantly more. Response to Arguments Applicant’s arguments, filed 05/29/2026, have been fully considered but are not persuasive for the following reasons. Applicant argues that the claimed computational method provides an improvement to the field of CNV determination, namely by using estimated source contributions of cell free nucleic acids based on a binomial distribution of counts to provide safer and more accurate CNV determinations compared to existing invasive procedures. In response, applicant is essentially arguing that the abstract idea (as set forth in the Step 2A, prong 1 analysis) provides the improvement to the technology by avoiding physical steps and applying specific computational analysis, e.g. binomial distributions, to provide ‘better data’. However, even if there is “an improvement in the relevant technology”, i.e. CNV method does not require invasive procedures, the purported improvement appears to lie within the judicial exception itself (alleged better calculation). It is well established that “the judicial exception alone cannot provide the improvement.” See MPEP § 2106.05(a). On this point, the courts have also instructed that “[t]he different use of a mathematical calculation, even one that yields different or better results, does not render patent eligible subject matter.” Board Of Trustees Of Leland Stanford Junior University, 991 F.3d 1245, 1251 (Fed. Cir. 2021). In summary, while appellant’s particular algorithmic approach may be a particular way to achieve an alternative solution for improving CNV calculations, the claimed invention is, nevertheless, directed to an improved algorithmic analysis. Contrary to applicant’s arguments regarding Vanda, the instant claims are not similar as they do not recite a particular treatment. As such, the claims do not integrate the recited judicial exception into a practical application. Applicant additionally argues that the Kingsley Declaration provides evidence of the improvement to the technology. In response, the MPEP is clear that the word "improvements" in the context of this consideration is limited to improvements to the functioning of a computer or any other technology/technical field, whether in Step 2A Prong Two or in Step 2B. MPEP 2106.04(d)(1). In this case, it is first noted that this declaration was written for related application 17/698,900, which (unlike instant claim 1) requires measuring a frequency of thirty-two or more informative loci from a first source comprising the minor source and a frequency of thirty-two or more informative loci from a second source comprising the major source and results in calculating, by the computer processor, a presence or absence of a CNV for one or more genomic regions by comparison of the frequency data from the two or more genomic regions from the combined first and second sources and the estimated contribution of cell free nucleic acids in the mixed sample. As such, the claims are directed to different fact patterns. That being said, the Kingsley declaration is also asserting that the related claims result in an improvement to the technology by using an estimated source contribution of cell free nucleic acids based on a binomial distribution of counts (which results in an improved determination of the presence or absence of CNV), i.e. the purported improvement appears to lie within the judicial exception itself (alleged better calculation). However, it is well established that “the judicial exception alone cannot provide the improvement.” See MPEP § 2106.05(a). Moreover, the declaration does not contend that it invented any new type of processors for purposes of performing the claimed invention. As such, the claimed invention does not appear to result in improvements to the functioning of a particular machine or add a specific limitation other than what is well-understood, routine, conventional activity in the field, e.g., a non-conventional and non-generic arrangement of various computer components. The claimed invention is directed to obtaining data, analyzing data, and generating a resulting calculation (presence/absence of CNV) and merely invokes generic computer elements for performing the claimed steps rather than a specific method that improves the relevant technology. Applicant additionally argues that the instant claim includes elements that are not well-understood, routine, and conventional given the lack of any cited evidence (Berkheimer Memo). In response, Applicant is reminded that it is improper to conflate 35 USC 101 analysis with prior art analysis under 35 USC 102/103. As made clear by the courts, the “‘novelty’ of any element or steps in a process, or even of the process itself, is of no relevance in determining whether the subject matter of a claim falls within the § 101 categories of possibly patentable subject matter.” Intellectual Ventures I v. Symantec Corp., 838 F.3d 1307, 1315, 120 USPQ2d 1353, 1358 (Fed. Cir. 2016). See MPEP 2106.05. In other words, it is true that claims can be free of the prior art and yet still rejected under 35 USC 101. That being said, as set forth above in the Step 2B analysis, a review of the specification teaches routine and conventional methods for measuring ‘loci’ frequency (e.g. sequencing or ‘counting’) [0015, 0061] and teaches routine and conventional computer hardware elements for performing the claimed method [0074-0077 and Figure 1]. Moreover, the courts have recognized the following laboratory techniques as well-understood, routine, conventional activity in the life science arts when they are claimed in a merely generic manner (e.g., at a high level of generality) or as insignificant extra-solution activity: i. Determining the level of a biomarker in blood by any means, Mayo, 566 U.S. at 79, 101 USPQ2d at 1968; Cleveland Clinic Foundation v. True Health Diagnostics, LLC, 859 F.3d 1352, 1362, 123 USPQ2d 1081, 1088 (Fed. Cir. 2017); ii. Using polymerase chain reaction to amplify and detect DNA, Genetic Techs. Ltd. v. Merial LLC, 818 F.3d 1369, 1376, 118 USPQ2d 1541, 1546 (Fed. Cir. 2016); Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1377, 115 USPQ2d 1152, 1157 (Fed. Cir. 2015); iii. Detecting DNA or enzymes in a sample, Sequenom, 788 F.3d at 1377-78, 115 USPQ2d at 1157); Cleveland Clinic Foundation 859 F.3d at 1362, 123 USPQ2d at 1088 (Fed. Cir. 2017); v. Analyzing DNA to provide sequence information or detect allelic variants, Genetic Techs. Ltd., 818 F.3d at 1377; 118 USPQ2d at 1546; Therefore, as discussed above and absent any evidence to the contrary, there is nothing unconventional with regards to the above non-abstract elements/steps. See MPEP 2106.05(d)(Part II). Thus, the examiner maintains that the independent claim(s) as a whole do not amount to significantly more than the exception itself. For at least these reasons, and absent any evidence to the contrary, the rejection is maintained. Claim rejections - 35 USC § 112, 2nd Paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. The following rejections are necessitated by amendment. Claims 3-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claims that depend directly or indirectly from claim(s) 3 and 5 is/are also rejected due to said dependency. Claims 3, 5, recite “calculating…the presence or absence of a CNV…by comparing empirical copy numbers of the one or more genomic regions...”. In this case, the artisan would recognize that data must be obtained before any type of evaluation can be made. However, in this case, there is no previous step in the claim that provides, calculates, or determines “empirical copy numbers” such that it can be subsequently used in a calculation as claimed. Accordingly, there is lack of antecedent basis for this limitation as the claimed “calculating” step is relying upon information that has not been previously introduced (and since copy number data is not inherently encompassed by the previously obtained frequency data). As a result, the claim is also rejected under 35 USC 112(b) for missing essential matter (e.g. obtaining empirical copy numbers) since it fails to interrelate the essential elements of the claimed invention. See also MPEP 2172.01. Clarification is requested via amendment. Claims 7, 8 recite “calculating a copy number variation for one or more genomic regions of a single source in the mixed sample by comparing empirical copy numbers of the one or more genomic regions…”. In this case, the artisan would recognize that data must be obtained before any type of evaluation can be made. However, in this case, there is no previous step in the claim that provides, calculates, or determines “empirical copy numbers” such that it can be subsequently used in a calculation as claimed. Accordingly, there is lack of antecedent basis for this limitation as the claimed “calculating” step is relying upon information that has not been previously introduced (and since copy number data is not inherently encompassed by the previously obtained frequency data). As a result, the claim is also rejected under 35 USC 112(b) for missing essential matter (e.g. obtaining empirical copy numbers) since it fails to interrelate the essential elements of the claimed invention. See also MPEP 2172.01. Clarification is requested via amendment. Non-Statutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b). Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claim(s) 3-8 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim(s) 16, 17, 34, 45, 46, 48, 50 of copending Application No. 13/605,505 (now US 8,712,697). The differences between the inventions defined by the conflicting claims are as follows: Reference claim(s) 16 of the ‘505 application teaches all of the limitations of instant claim(s) 3, 5, 7, 8 plus additional features and/or limitations. Therefore, instant claim(s) 3-8 is/are anticipated by the narrower claims (i.e. species anticipates the genus). Claim(s) 3-8 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim(s) 1-14, 16, 17 of copending Application No. 14/176,858 (now US 10,847,250). The differences between the inventions defined by the conflicting claims are as follows: Reference claim(s) 16 of the ‘858 application teaches all of the limitations of instant claim(s) 3, 5, 7, 8 plus additional features and/or limitations. Therefore, instant claim(s) 3-8 is/are anticipated by the narrower claims (i.e. species anticipates the genus). Claim(s) 3-8 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim(s) 1, 9-15, 17-22 of copending Application No. 14/176,830 (now US 11,289,176). The differences between the inventions defined by the conflicting claims are as follows: Reference claim(s) 1 of the ‘830 application teaches all of the limitations of instant claim(s) 3, 5, 7, 8 except for the feature of informative loci being from a fetal source and maternal source. However, dependent ref. claim 22 teaches these limitations. Therefore, instant claim 3, 5, 7, 8 are made obvious over the COMBINATION of reference claims 1 and 22, because it would have been obvious to COMBINE all limitations taught in the reference claims. Response to Arguments Applicant’s request that the double patenting rejections be held in abeyance is denied, as applicant has not argued the merits of these rejections and no terminal disclaimer(s) in compliance with 37 C.F.R. 1.321 (c) have been filed to overcome these rejections, as required by 37 C.F.R. 1.130(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PABLO S WHALEY whose telephone number is (571)272-4425. The examiner can normally be reached between 1pm-9pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anita Coope can be reached at 571-270-3614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PABLO S WHALEY/Primary Examiner, Art Unit 3619
Read full office action

Prosecution Timeline

Mar 18, 2022
Application Filed
Sep 04, 2025
Non-Final Rejection mailed — §101, §112, §DP
Dec 04, 2025
Response Filed
Mar 03, 2026
Final Rejection mailed — §101, §112, §DP
May 29, 2026
Response after Non-Final Action
May 29, 2026
Request for Continued Examination
Jun 03, 2026
Response after Non-Final Action
Aug 10, 2026
Non-Final Rejection mailed — §101, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12718954
Unsupervised Machine Learning Methods
2y 0m to grant Granted Aug 25, 2026
Patent 12688905
SAMPLE CONTAMINATION DETECTION OF CONTAMINATED FRAGMENTS WITH CPG-SNP CONTAMINATION MARKERS
2y 12m to grant Granted Jul 21, 2026
Patent 12633374
METHOD FOR DETERMINING EFFICACY OF CHEMOTHERAPY TREATMENT FOR A SUBJECT
4y 11m to grant Granted May 19, 2026
Patent 12620473
A METHOD AND DOSING CONTROLLER FOR ADMINSTERING A CORRECTION DOSE OF INSULIN
2y 11m to grant Granted May 05, 2026
Patent 12288620
A METHOD AND SYSTEM FOR INSULIN MANAGEMENT
1y 7m to grant Granted Apr 29, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
25%
Grant Probability
46%
With Interview (+21.4%)
5y 2m (~7m remaining)
Median Time to Grant
High
PTA Risk
Based on 544 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month